News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,516 Results
Type
Article (436)
Company Profile (4)
Press Release (18076)
Section
Business (9468)
Career Advice (8)
Deals (1373)
Drug Development (1509)
FDA (280)
Job Trends (646)
News (12045)
Policy (688)
Tag
Academia (60)
Allergies (2)
Alliances (659)
ALS (1)
Alzheimer's disease (20)
Antibody-drug conjugate (ADC) (7)
Approvals (296)
Artificial intelligence (8)
Autoimmune disease (1)
Automation (1)
Bankruptcy (3)
Best Places to Work (645)
Biosimilars (2)
Biotechnology (1)
Bladder cancer (2)
Brain cancer (1)
Breast cancer (22)
Cancer (107)
Cardiovascular disease (5)
Career advice (7)
CAR-T (2)
Cell therapy (7)
Cervical cancer (1)
Clinical research (1301)
Collaboration (13)
Compensation (15)
Complete response letters (1)
COVID-19 (97)
CRISPR (1)
C-suite (4)
Cystic fibrosis (2)
Data (144)
Depression (3)
Diabetes (4)
Diagnostics (208)
Drug discovery (3)
Drug pricing (2)
Duchenne muscular dystrophy (1)
Earnings (8944)
Events (1573)
Executive appointments (5)
FDA (430)
Frontotemporal dementia (2)
Funding (18)
Gene editing (3)
Gene therapy (7)
GLP-1 (15)
Government (147)
Guidances (100)
Healthcare (700)
HIV (2)
Huntington's disease (1)
Indications (3)
Infectious disease (100)
Inflammatory bowel disease (5)
Intellectual property (3)
Interviews (3)
IPO (1126)
Job creations (23)
Job search strategy (3)
JPM (3)
Kidney cancer (1)
Labor market (2)
Layoffs (6)
Legal (116)
Liver cancer (3)
Lung cancer (10)
Lymphoma (12)
Machine learning (1)
Manufacturing (6)
MASH (3)
Medical device (824)
Medtech (828)
Mergers & acquisitions (254)
Metabolic disorders (17)
Multiple sclerosis (1)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (40)
NextGen: Class of 2026 (146)
Non-profit (86)
Now hiring (1)
Obesity (6)
Ovarian cancer (5)
Pain (2)
Pancreatic cancer (2)
Parkinson's disease (3)
Partnered (2)
Patents (4)
Patient recruitment (3)
Peanut (1)
People (651)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase 1 (323)
Phase 2 (529)
Phase 3 (608)
Pipeline (378)
Policy (3)
Postmarket research (42)
Preclinical (128)
Prostate cancer (2)
Radiopharmaceuticals (8)
Rare diseases (12)
Real estate (68)
Regulatory (498)
Reports (2)
Research institute (58)
Resumes & cover letters (1)
Rett syndrome (1)
RSV (3)
Schizophrenia (6)
Series A (2)
Series B (3)
Service/supplier (1)
Sickle cell disease (2)
Spinal muscular atrophy (4)
Startups (37)
Supply chain (1)
Vaccines (12)
Weight loss (7)
Women's health (4)
Date
Last 7 days (14)
Last 30 days (40)
Last 365 days (992)
2026 (47)
2025 (1006)
2024 (1301)
2023 (1550)
2022 (1553)
2021 (1570)
2020 (4666)
2019 (1068)
2018 (870)
2017 (580)
2016 (357)
2015 (547)
2014 (320)
2013 (202)
2012 (268)
2011 (327)
2010 (337)
Location
Africa (9)
Alabama (2)
Alaska (1)
Arizona (5)
Asia (1021)
Australia (96)
California (362)
Canada (78)
China (20)
Colorado (35)
Connecticut (16)
Delaware (8)
Europe (2100)
Florida (53)
Georgia (10)
Idaho (1)
Illinois (47)
India (2)
Indiana (31)
Japan (10)
Kansas (49)
Kentucky (3)
Louisiana (6)
Maine (3)
Maryland (38)
Massachusetts (218)
Michigan (10)
Minnesota (27)
Missouri (6)
Montana (1)
Nevada (1)
New Hampshire (3)
New Jersey (90)
New York (69)
North Carolina (40)
Northern California (191)
Ohio (8)
Oklahoma (1)
Oregon (1)
Pennsylvania (86)
South America (21)
South Carolina (2)
Southern California (144)
Tennessee (2)
Texas (108)
United States (1391)
Utah (18)
Virginia (3)
Washington State (41)
Wisconsin (4)
18,516 Results for "214".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry
January 6, 2026
·
3 min read
Press Releases
U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia
November 5, 2025
·
2 min read
Business
J&J Beats Q4 Expectations, Reports $21.4B in Revenue as Faces Patent Cliff
Johnson & Johnson exceeded fourth-quarter earnings estimates, reporting nearly $21.4 billion in revenue, as its pharma business faces a patent cliff with Stelara competition entering the market.
January 23, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
December 16, 2024
·
31 min read
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
JW Therapeutics announced the initiation of clinical study of JWATM214 in patients with advanced hepatocellular carcinoma and the first patient infusion.
February 28, 2023
·
4 min read
Drug Development
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
July 9, 2024
·
5 min read
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
Lexaria Bioscience Corp. is pleased to announce additional findings from last year’s human clinical study HYPER-H21-4 (“the Study”) demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (“CVD”) and a host of other conditions.
May 23, 2023
·
10 min read
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 (“the Study”) demonstrating a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure (“BP”).
February 21, 2023
·
6 min read
Collagen Market Size to Hit USD 21.4 Billion by 2030
According to Nova one advisor, the global Collagen market size is expected to hit around USD 21.4 billion by 2030 from valued at USD 10.5 billion in 2021 and growing at a CAGR of 9.2% from 2022 to 2030.
October 3, 2022
·
7 min read
Monkeypox Vaccine And Treatment Market Size to Hit USD 214.79 mn by 2030
According to Nova one advisor, the global Monkeypox Vaccine And Treatment market size is expected to hit around USD 214.79 million by 2030 from valued at USD 85.43 million in 2022 and growing at a CAGR of 10.26% from 2022 to 2030.
October 6, 2022
·
8 min read
1 of 1,852
Next